Astellas completed acquisition of Cambridge, MA-based Mitobridge in January 2018 for $225M upfront plus up to $225M in development milestones (total $450M). Built off a 2013 collaboration option, the deal accelerates Astellas's R&D in diseases linked to mitochondrial dysfunction, anchored by lead PPAR-delta modulator ASP0367 for primary mitochondrial myopathies.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 5yr post-close.
Key facts
AnnouncedJan 23, 2018
ClosedJan 23, 2018
Deal value$450M
Deal typeAcquisition/Merger
Therapeutic areaPrimary mitochondrial myopathies
IndicationsPrimary mitochondrial myopathies
Key assetsASP0367/MA-0211 (PPAR-delta modulator)
MechanismSelective PPAR-delta modulator enhancing mitochondrial function